Food Allergy Science Initiative and Vie Ventures Announce Strategic Collaboration to Accelerate Progress Toward a Cure for Food Allergies
The Food Allergy Science Initiative (FASI) today announced that it has joined Vie Ventures as a strategic collaborator. FASI will join Vie Ventures’ growing network of Strategic Collaborators, bringing world-leading expertise in food allergy and translational science to a collaborative effort aimed at accelerating the development of novel therapies across immune-mediated diseases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623532721/en/
As a Strategic Collaborator, FASI will contribute scientific and clinical expertise to Vie Ventures’ investment and portfolio development activities, help identify emerging opportunities in food allergy and related allergic and type 2 inflammatory diseases, and participate in broader cross-disease collaborations designed to advance therapeutic innovation.
“From the beginning, FASI has brought together leading scientific minds working across disciplines, assembling a team of top researchers discovering actionable, cross-disciplinary insights into preventing, treating, and managing food allergies,” said Dr. Erin Straub, director of strategic partnerships and business operations for FASI. “Teaming up with Vie Ventures makes sense and will further accelerate our progress in finding a cure for food allergies.”
